Company intelligence / Profile preview

Biocogniv

South Burlington, Vermont, United Statesbiocogniv.com ↗

Ownership: Private
Development stage: Commercial

Overview

Biocogniv’s lead product, Sepsis aiMarker™, can predict sepsis up to 72 hours before onset using routine lab data. It has received FDA Breakthrough Device Designation. The company’s technology has been validated with real-world data from hundreds of hospitals and strategic partners. Their AI-COVID tool was used at the University of Texas Medical Branch to increase laboratory throughput during the pandemic.

Therapeutic areas: OtherInfectious Diseases
Modalities: Device (AI-based diagnostic software)Non-pharmacological therapy (predictive diagnostics)Digital health platform
Industry: Digital Health Medical Devices

Partnerships

University of Vermont/Cedars-Sinai Medical Center (academic validation/collaboration)University of Texas Medical Branch (clinical deployment)

Beyond the preview

Go deeper on Biocogniv.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biocogniv.

Explore the full profile